Expertise in
13
conditions

Dr. Helen L. Frederickson

Oncology
Monument Health Rapid City Hospital
353 Fairmont Blvd, 
Rapid City, SD 
Accepting New Patients
Expertise in
13
conditions
Monument Health Rapid City Hospital
353 Fairmont Blvd, 
Rapid City, SD 

Overview

Helen Frederickson is an Oncologist practicing medicine in Rapid City, South Dakota.

Dr. Frederickson is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Bladder Reconstruction, and Hernia Surgery.

She is actively involved in clinical research, participating in 8 clinical trials. Dr. Frederickson is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in SD

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Avera Health
  • HMO
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

Monument Health Rapid City Hospital
353 Fairmont Blvd, Rapid City, SD 57701

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Monument Health Rapid City Hospital

353 Fairmont Blvd, 
Rapid City, SD 
 (0.1 miles away)
605-719-2360
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Petereit is an Oncologist practicing medicine in Rapid City, South Dakota. Dr. Petereit is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Cervical Cancer, and Breast Cancer. Dr. Petereit is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Monument Health Rapid City Hospital

353 Fairmont Blvd, 
Rapid City, SD 
 (0.1 miles away)
605-755-1000
Languages Spoken:
English, Creoles And Pidgins
See accepted insurances
Accepting New Patients

Than Than-Aye is an Oncologist practicing medicine in Rapid City, South Dakota. Dr. Than-Aye is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Breast Cancer. Dr. Than-Aye is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Monument Health Rapid City Hospital

353 Fairmont Blvd, 
Rapid City, SD 
 (0.1 miles away)
605-719-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Swartz is an Oncologist practicing medicine in Rapid City, South Dakota. Dr. Swartz is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Breast Cancer, and Paget Disease of the Breast. Dr. Swartz is currently accepting new patients.

Frequently Asked Questions about Dr. Helen L. Frederickson

How do I make an appointment with Dr. Helen L. Frederickson?

You can book an appointment with Dr. Helen L. Frederickson by calling their office at 605-755-2300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Helen L. Frederickson a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Helen L. Frederickson is classified as an Distinguished expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Helen L. Frederickson specialize in?

While Dr. Helen L. Frederickson is a Oncology, they have specific expertise in Endometrial Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Helen L. Frederickson accept my insurance?

Dr. Helen L. Frederickson accepts most major insurance plans, including Avera Health and Blue Cross Blue Shield. We recommend calling the office directly at 605-755-2300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Frederickson's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile